Clinical Trials Browser

Approved for marketing × Afatinib × Clear all

NCT01931306 2018-11-14

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Approved for marketing

Carcinoma, Non-Small-Cell Lung

NCT01649284 2016-11-30

Afatinib Expanded Access Program

Approved for marketing

Carcinoma, Non-Small-Cell Lung

NCT01209650 2016-11-10

LUX Lung Special Access Scheme Australia Named Patient Use (NPU)

Approved for marketing

Carcinoma, Non-Small-Cell Lung